Intra-Cellular Therapies (ITCI) Tops Q2 EPS by 8c

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q2 EPS of ($0.71), $0.08 better than the analyst estimate of ($0.79). Revenue for the quarter came in at $223.45 thousand versus the consensus estimate of $20 thousand.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance
• UBS Reiterates Buy Rating on General Motors (GM) as Defense Opportunity in Focus